News

This work is the first of its kind to demonstrate that this functional human protein can be produced in plant cells.

This week, Danaher announced a definitive agreement to purchase General Electric's Biopharma business for a cash purchase price of $21.4 billion. Factoring tax benefits from the structure of the deal, the net purchase price is about $20 billion.

The pioneering clinical trials program delivered an experimental treatment directly to the brain. The trial results offer hope that it may be possible to restore the cells damaged in Parkinson’s.

The commercially developed ReleafApp is a publicly available, incentive-free app for educating patients on how their type of product affects their symptom severity levels.

Rescuing T cell glycolysis could help T cells maintain the ability to compete with cancer cells, and improve responsiveness to cancer immunotherapy.

In the quest to develop an effective HIV vaccine, researchers have focused attention on identifying and targeting the region of the virus’s outer envelope where a lineage of antibodies are able to dock and neutralize the virus.

With multidrug-resistant infections on the rise, the first US clinical trial of intravenously administered bacteriophage therapy has received FDA approval.

A new study in mice has explored why certain antibodies are highly effective in protecting the body against debilitating viruses like chikungunya.

A stem cell therapy has been given the green light for the treatment of spinal cord injuries, and a follow-up trial is set to begin later this year. However, independent researchers warn that the approval is premature.

The microfluidic device with interlinking modules containing human-derived heart, liver, skeletal muscle and nervous system cells was able to maintain cellular viability and record cellular function in real-time for 28 days.